Egalet Corp. Company Profile (NASDAQ:EGLT)

About Egalet Corp.

Egalet Corp. logoEgalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EGLT
  • CUSIP:
Key Metrics:
  • Previous Close: $7.71
  • 50 Day Moving Average: $7.61
  • 200 Day Moving Average: $6.54
  • 52-Week Range: $4.34 - $13.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.11
  • P/E Growth: 0.00
  • Market Cap: $189.23M
  • Outstanding Shares: 24,543,000
  • Beta: 0.26
  • Net Margins: -244.57%
  • Return on Equity: -86.03%
  • Return on Assets: -40.58%
  • Debt-to-Equity Ratio: 1.02%
  • Current Ratio: 3.68%
  • Quick Ratio: 3.62%
Additional Links:
Companies Related to Egalet Corp.:

Analyst Ratings

Consensus Ratings for Egalet Corp. (NASDAQ:EGLT) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $15.63 (102.66% upside)

Analysts' Ratings History for Egalet Corp. (NASDAQ:EGLT)
DateFirmActionRatingPrice TargetDetails
9/13/2016GabelliInitiated CoverageBuy$9.50View Rating Details
9/8/2016Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details
3/14/2016Janney Montgomery ScottInitiated CoverageNeutral$8.00View Rating Details
9/30/2015GuggenheimReiterated RatingBuy$24.00View Rating Details
8/7/2015Canaccord GenuityReiterated RatingBuyView Rating Details
3/26/2015JMP SecuritiesBoost Price TargetOutperform$18.00 -> $24.00View Rating Details
(Data available from 9/30/2014 forward)


Earnings History for Egalet Corp. (NASDAQ:EGLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.82)($0.97)$3.83 million$3.45 millionViewN/AView Earnings Details
5/10/2016Q116($0.87)($0.76)$3.50 million$2.70 millionViewListenView Earnings Details
3/8/2016Q415($0.91)($0.28)$2.80 million$2.10 millionViewN/AView Earnings Details
11/4/2015Q315($0.90)($0.81)$1.62 million$1.30 millionViewN/AView Earnings Details
8/6/2015Q215($1.02)($0.98)$1.47 millionViewN/AView Earnings Details
5/7/2015($0.98)($1.02)ViewN/AView Earnings Details
3/25/2015Q414($0.69)($0.48)$5.64 millionViewN/AView Earnings Details
11/12/2014Q314($0.77)($0.63)ViewN/AView Earnings Details
8/12/2014Q214($0.42)($0.73)ViewN/AView Earnings Details
5/13/2014Q114($0.16)($1.39)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Egalet Corp. (NASDAQ:EGLT)
Current Year EPS Consensus Estimate: $-3.48 EPS
Next Year EPS Consensus Estimate: $-2.48 EPS


Dividend History for Egalet Corp. (NASDAQ:EGLT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Egalet Corp. (NASDAQ:EGLT)
Insider Ownership Percentage: 13.20%
Institutional Ownership Percentage: 67.18%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/6/2016Robert S RadieCEOSell15,000$5.01$75,150.00View SEC Filing  
7/5/2016Robert S RadieCEOSell5,000$4.94$24,700.00View SEC Filing  
7/5/2016Stan MusialCFOSell13,480$5.06$68,208.80View SEC Filing  
7/1/2016Robert S RadieCEOSell5,000$5.07$25,350.00View SEC Filing  
7/1/2016Stan MusialCFOSell10,000$5.06$50,600.00View SEC Filing  
6/30/2016Jeffrey M DaynoInsiderSell536$4.65$2,492.40View SEC Filing  
4/5/2016Deanne F MelloyInsiderSell860$6.96$5,985.60View SEC Filing  
4/5/2016Robert S RadieCEOSell5,000$6.99$34,950.00View SEC Filing  
4/4/2016Robert S RadieCEOSell10,000$6.97$69,700.00View SEC Filing  
1/11/2016Robert S. RadieCEOSell10,000$9.65$96,500.00View SEC Filing  
1/6/2016Robert S. RadieCEOSell5,000$10.52$52,600.00View SEC Filing  
10/6/2015Deanne F MelloyInsiderSell860$11.42$9,821.20View SEC Filing  
10/1/2015Robert S RadieCEOSell15,000$12.27$184,050.00View SEC Filing  
10/1/2015Stan MusialCFOSell8,480$12.32$104,473.60View SEC Filing  
9/30/2015Mark StrobeckInsiderSell5,220$12.56$65,563.20View SEC Filing  
7/8/2015Robert S RadieCEOSell6,000$11.97$71,820.00View SEC Filing  
7/6/2015Robert S RadieCEOSell9,000$12.53$112,770.00View SEC Filing  
7/1/2015Mark StrobeckInsiderSell10,440$12.98$135,511.20View SEC Filing  
7/1/2015Stan MusialCFOSell8,480$13.20$111,936.00View SEC Filing  
4/1/2015Robert S RadieCEOSell11,130$11.25$125,212.50View SEC Filing  
2/3/2015Jeffrey M DaynoInsiderSell2,500$8.87$22,175.00View SEC Filing  
1/2/2015Mark StrobeckInsiderSell3,480$5.09$17,713.20View SEC Filing  
1/2/2015Robert S RadieCEOSell11,130$5.11$56,874.30View SEC Filing  
9/10/2014Robert S RadieCEOSell40,040$9.61$384,784.40View SEC Filing  
9/8/2014Robert S RadieCEOSell49,000$9.74$477,260.00View SEC Filing  
8/13/2014Mark StrobeckInsiderSell5,135$9.20$47,242.00View SEC Filing  
8/11/2014Mark StrobeckInsiderSell5,700$10.28$58,596.00View SEC Filing  
8/7/2014Mark StrobeckInsiderSell3,085$11.50$35,477.50View SEC Filing  
8/7/2014Stan MusialCFOSell13,920$11.05$153,816.00View SEC Filing  
2/11/2014Jean Francois FormelaDirectorBuy41,667$12.00$500,004.00View SEC Filing  
2/11/2014Life Science Ventures SunstoneMajor ShareholderBuy133,333$12.00$1,599,996.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Egalet Corp. (NASDAQ:EGLT)
DateHeadline logoEditorial Discussing Approaches to Category 1 Testing of Abuse-Deterrent Formulations of Opioids Published in Pain Practice (NASDAQ:EGLT) - September 27 at 9:23 AM logoEgalet (EGLT) Announces Publication of Significant ARYMO ER Data - (NASDAQ:EGLT) - September 22 at 4:52 PM logo6:03 am Egalet announces results from a Category 3 oral human abuse potential study and a Category 3 intranasal HAP study of product candidate Arymo ER extended-release tablets have been published in Pain Medicine (NASDAQ:EGLT) - September 22 at 4:52 PM logoEgalet Announces Publications in Pain Medicine from ARYMO™ ER Oral and Intranasal Human Abuse Potential Studies (NASDAQ:EGLT) - September 22 at 10:22 AM logoEgalet (EGLT) Announces Publication of Significant ARYMO ER Data (NASDAQ:EGLT) - September 22 at 10:22 AM
News IconBuzzer on Short Call- Tesla Motors (NASDAQ:TSLA), Egalet Corporation (NASDAQ:EGLT), Bitauto Holdings (NYSE ... - Seneca Globe (NASDAQ:EGLT) - September 19 at 3:39 PM logoETF’s with exposure to Egalet Corp. : September 19, 2016 (NASDAQ:EGLT) - September 19 at 3:39 PM logoEgalet appoints Patrick Shea as CCO (NASDAQ:EGLT) - September 19 at 9:27 AM logoEgalet Appoints Patrick Shea as Chief Commercial Officer (NASDAQ:EGLT) - September 19 at 9:27 AM logoRecent Survey Shows Americans with Chronic Pain (NASDAQ:EGLT) - September 15 at 5:07 PM
News IconEgalet Corp. (NASDAQ: EGLT) Stock Coverage Initiated at Gabelli - The Woodbridge Citizen (NASDAQ:EGLT) - September 14 at 9:58 PM logoCoverage initiated on Egalet by Gabelli & Co (NASDAQ:EGLT) - September 13 at 9:39 AM logoEgalet (EGLT) Announces Positive Top-Line Data for OXAYDO vs Roxicodone (NASDAQ:EGLT) - September 12 at 4:39 PM logoEgalet (EGLT) Announces Positive Top-Line Data for OXAYDO vs Roxicodone - (NASDAQ:EGLT) - September 12 at 9:42 AM logoEgalet Announces OXAYDO® Demonstrates Bioequivalence at 15 mg Dose (NASDAQ:EGLT) - September 12 at 9:42 AM logoExclusive: Egalet CFO Talks 'Hot Button' Rx Abuse-Deterrence, Pipeline And Multimillion-Dollar Financing - Benzinga (NASDAQ:EGLT) - September 9 at 4:39 PM
News IconStock Tracker: Earnings & Estimates for Egalet Corporation ... - Frisco Fastball (NASDAQ:EGLT) - September 9 at 9:36 AM
News IconEgalet Corp. (NASDAQ: EGLT) stock reaffirmed at Cantor Fitzgerald - BNB Daily (blog) (NASDAQ:EGLT) - September 9 at 9:36 AM logoEgalet Announces Category 1 Abuse-Deterrent Data Demonstrating OXAYDO® Resists Syringeability (NASDAQ:EGLT) - September 8 at 4:42 PM
News IconEgalet seals secured debt offering of $40M to support its pipeline of abuse-deterrent pain meds (NASDAQ:EGLT) - September 6 at 9:38 AM logoEGALET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agre (NASDAQ:EGLT) - September 1 at 4:42 PM
News IconEgalet Completes $40 Million Secured Debt Financing (NASDAQ:EGLT) - September 1 at 7:43 AM logoEGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:EGLT) - August 26 at 4:11 PM logoEgalet Announces Scientific Presentations at PAINWeek 2016 Meeting (NASDAQ:EGLT) - August 25 at 9:46 AM logoEgalet (EGLT) in Focus: Stock Moves 7.2% Higher in Session (NASDAQ:EGLT) - August 24 at 4:45 PM logoETF’s with exposure to Egalet Corp. : August 17, 2016 (NASDAQ:EGLT) - August 17 at 4:58 PM logoEGALET CORP Financials (NASDAQ:EGLT) - August 16 at 4:53 PM logoAbuse-Deterrent Drugs: A Growing Field (NASDAQ:EGLT) - August 16 at 8:01 AM logoEgalet Corporation Scores Huge Vote Of Support From FDA Advisory Panel For Its ARYMO Compound (NASDAQ:EGLT) - August 12 at 4:48 PM logoEgalet Corp. :EGLT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:EGLT) - August 12 at 4:48 PM logoValuable Analysts Trends to Observe: Egalet Corporation (NASDAQ:EGLT) , BioDelivery Sciences International, Inc ... - Street Updates (NASDAQ:EGLT) - August 9 at 3:27 PM
News IconNotable Traders Recap: Fairchild Semiconductor Intl Inc (NASDAQ:FCS), Egalet Corp (NASDAQ:EGLT) - NYSE Journal (press release) (NASDAQ:EGLT) - August 8 at 10:07 PM logoFriday Market Review – Stock Gaps Up (NASDAQ:EGLT) - August 8 at 9:36 AM logoEgalet Corporation (EGLT) Jumps 6.82% on August 05 - (NASDAQ:EGLT) - August 6 at 7:58 AM logoFDA committees recommend approval of Eaglet's abuse-deterrent pain medicine (NASDAQ:EGLT) - August 5 at 10:01 PM logoEgalet (EGLT) Receives FDA Panel Recommendation for ARYMO ER for Pain Management (NASDAQ:EGLT) - August 5 at 10:01 PM
News IconFDA Advisory Panels Back Egalet’s (EGLT) Drug; Rackspace Hosting (RAX) Gets Bullish On Possible Takeover Deal (NASDAQ:EGLT) - August 5 at 10:01 PM
News IconEgalet Corp. announces quarterly earnings (EGLT) - BNB Daily (blog) (NASDAQ:EGLT) - August 5 at 4:49 PM logoEGALET CORP Files SEC form 10-Q, Quarterly Report (NASDAQ:EGLT) - August 5 at 4:49 PM logoEgalet reports 2Q loss (NASDAQ:EGLT) - August 5 at 8:16 AM logoEgalet Corporation (EGLT) Jumps 8.09% on August 03 - (NASDAQ:EGLT) - August 4 at 10:30 PM logoEGALET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial St (NASDAQ:EGLT) - August 4 at 10:30 PM logoU.S. panel backs approval of Egalet's abuse-resistant painkiller (NASDAQ:EGLT) - August 4 at 4:59 PM logoEgalet Announces FDA Advisory Committees Recommend Approval of Abuse-Deterrent ARYMO™ ER (Morphine Sulfate) and Reports Second Quarter 2016 Financial Results (NASDAQ:EGLT) - August 4 at 4:59 PM logoQ2 2016 Egalet Corp Earnings Release - Before Market Open (NASDAQ:EGLT) - August 4 at 7:43 AM logoEgalet Corporation (EGLT) Drops 5.01% on August 01 - (NASDAQ:EGLT) - August 3 at 7:34 AM logoNew Broker Ratings For Egalet Corp (EGLT) - FTSE News (NASDAQ:EGLT) - July 29 at 10:07 PM logoEgalet Corporation (EGLT) Jumps 8.54% on July 27 - (NASDAQ:EGLT) - July 28 at 8:43 AM
News IconIncreased Volatility Noted on Shares of: Egalet Corporation (NASDAQ:EGLT) - Engelwood Daily (NASDAQ:EGLT) - July 23 at 8:53 AM logoEgalet Corporation (EGLT) Jumps 5.47% on July 22 - (NASDAQ:EGLT) - July 23 at 8:53 AM


Egalet Corp. (NASDAQ:EGLT) Chart for Friday, September, 30, 2016

Last Updated on 9/30/2016 by Staff